ZYVERSA THERAPEUTICS, INC. Research and Development Expense
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Research and Development Expense of $57.62 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $57.62K, a 77.74% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $79.24K, a 34.64% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $365.05K, a 16.28% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-06-30 was $409.94K, a 42.18% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $1.11M, a 37.44% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $1.78M, a 44.53% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $3.21M.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 11 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $57.62K 10-Q · filed 2026-05-13 | $136.86K derived: sum of 2 quarters · filed 2026-05-13 | $501.91K derived: sum of 3 quarters · filed 2026-05-13 | $911.85K derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-12-31 | $79.24K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $444.29K derived: sum of 2 quarters · filed 2026-03-31 | $854.23K derived: sum of 3 quarters · filed 2026-03-31 | $1.11M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $365.05K 10-Q · filed 2025-11-19 | $774.99K derived: sum of 2 quarters · filed 2025-11-19 | $1.03M 10-Q · filed 2025-11-19 | $1.16M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-06-30 | $409.94K 10-Q · filed 2025-08-13 | $668.81K 10-Q · filed 2025-08-13 | $790.06K derived: sum of 3 quarters · filed 2026-05-13 | $1.23M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-03-31 | $258.88K 10-Q · filed 2026-05-13 | $380.12K derived: sum of 2 quarters · filed 2026-05-13 | $816.16K derived: sum of 3 quarters · filed 2026-05-13 | $1.53M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $121.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $557.29K derived: sum of 2 quarters · filed 2026-03-31 | $1.27M derived: sum of 3 quarters · filed 2026-03-31 | $1.78M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $436.04K 10-Q · filed 2025-11-19 | $1.15M derived: sum of 2 quarters · filed 2025-11-19 | $1.66M 10-Q · filed 2025-11-19 | $1.92M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $709.05K 10-Q · filed 2025-08-13 | $1.22M 10-Q · filed 2025-08-13 | $1.48M derived: sum of 3 quarters · filed 2025-08-13 | $2.15M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $512.94K 10-Q · filed 2025-05-12 | $770.05K derived: sum of 2 quarters · filed 2025-05-12 | $1.44M derived: sum of 3 quarters · filed 2025-05-12 | $2.66M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $257.11K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $931.05K derived: sum of 2 quarters · filed 2025-03-27 | $2.15M derived: sum of 3 quarters · filed 2025-03-27 | $3.21M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $673.94K 10-Q · filed 2024-11-14 | $1.89M derived: sum of 2 quarters · filed 2024-11-14 | $2.95M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $1.22M 10-Q · filed 2024-08-09 | $2.28M 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | $1.06M 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $399.89K 10-K · filed 2024-03-25 | |||||
| 2022-12-12 | $5.41M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |